ADAMTS5 and Duchenne muscular dystrophy: Similarly, the ELISA data showed good normalisation after treatment with low inter-sample variation, thereby suggesting that ADAMTS5 may be useful as a biomarker for monitoring the response to therapy in DMD patients.